Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New feature:   Automatically detect candlestick patterns on any chart

Read How
Market News Market Pulse Stocks News ETF News Crypto News

Jasper Therapeutics, Inc.

Contributing Author

Recent Articles by Jasper Therapeutics, Inc.

Aug-14
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update JSPR -8.46% GlobeNewswire
Jun-01
Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value JSPR -35.56% GlobeNewswire
May-14
Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update JSPR JSPR -11.36% GlobeNewswire
Mar-30
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update JSPR -14.29% GlobeNewswire
Feb-24
Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference JSPR GlobeNewswire
Jan-08
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria JSPR -19.02% GlobeNewswire
Jan-07
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth JSPR +7.89% GlobeNewswire
Dec-02
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation JSPR -8.14% GlobeNewswire
Dec-01
Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation JSPR -6.52% GlobeNewswire
Nov-10
Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update JSPR GlobeNewswire
Nov-04
Jasper Therapeutics to Present at Upcoming Investor Conferences JSPR -13.81% GlobeNewswire
Sep-19
Jasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants JSPR GlobeNewswire
Sep-18
Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants JSPR +11.16% GlobeNewswire
Aug-27
Jasper Therapeutics to Present at Upcoming Investor Conferences JSPR GlobeNewswire
Aug-13
Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update JSPR GlobeNewswire
Jul-09
Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway JSPR +21.85% GlobeNewswire
Jul-07
Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria JSPR -55.10% GlobeNewswire
Jun-14
Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria JSPR GlobeNewswire
Jun-03
Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress JSPR +8.26% GlobeNewswire
May-14
Jasper Therapeutics to Present at Upcoming Investor Conferences JSPR GlobeNewswire
May-12
Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update JSPR GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)